An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis
Brief description of study
The purpose of the study is to determine the safety and tolerability of ATA188 in subjects with progressive forms of multiple sclerosis. Up to 42 male or female subjects with progressive forms of MS and 42 subjects with Relapsing-Remitting MS will be enrolled. The subjects will be randomized to receive study drug or placebo and will receive 2 treatment cycles followed by 11 monthly follow-up visits.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
TBD
-
Age: - 99 Years
-
Gender: All
Updated on
11 Aug 2022.
Study ID: 830135